Skip to main content
Top
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

RETRACTED ARTICLE: Pokemon and MEF2D co-operationally promote invasion of hepatocellular carcinoma

Authors: Xin Hong, Xing-Yu Hong, Tao Li, Cheng-Yan He

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is one of the most deadly human malignancy, and frequent invasion and metastasis is closely associated with its poor prognosis. However, the molecular mechanism underlying HCC invasion is still not completely elucidated. Pokemon is a well-established oncogene for HCC growth, but its contribution to HCC invasion has not been studied yet. In this paper, Pokemon was found to be overexpressed in MHCC-97H HCC cell line, which possesses higher invasiveness. Downregulation of Pokemon abolished the invasion of MHCC-97H HCC cell lines. Pokemon overexpression was able to enhance the invasion of MHCC-97L cells with lower invasiveness. MEF2D, an oncogene promoting the invasion of HCC cells, was further detected to be upregulated and downregulated when Pokemon was overexpressed and silenced, respectively. Online database analysis indicated that one Pokemon recognition site was located within the promoter of MEF2D. Chromatin co-precipitation, luciferase, and qPCR assays all proved that Pokemon can promote the expression of MEF2D in HCC cells. Restoration of MEF2D expression can prevent the impaired invasion of HCC cells with Pokemon silencing, while suppression of MEF2D abolished the effect of Pokemon overexpression on HCC invasion. More interestingly, MEF2D was also found to increase the transcription of Pokemon by binding myocyte enhancer factor 2 (MEF2) sites within its promoter region, implying an auto-regulatory circuit consisting of these two oncogenes that can promote HCC invasion. Our findings can contribute to the understanding of molecular mechanism underlying HCC invasion, and provided evidence that targeting this molecular loop may be a promising strategy for anti-invasion therapy.
Literature
1.
go back to reference Zhao X, Ning Q, Sun X, Tian D. Pokemon reduces Bcl-2 expression through NF-kappa Bp65: a possible mechanism of hepatocellular carcinoma. Asian Pac J Tro Med. 2011;4(6):492–7.CrossRef Zhao X, Ning Q, Sun X, Tian D. Pokemon reduces Bcl-2 expression through NF-kappa Bp65: a possible mechanism of hepatocellular carcinoma. Asian Pac J Tro Med. 2011;4(6):492–7.CrossRef
2.
go back to reference Lin CC, Zhou JP, Liu YP, Liu JJ, Yang XN, Jazag A, et al. The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. PLoS One. 2012;7(12), e51916.CrossRef Lin CC, Zhou JP, Liu YP, Liu JJ, Yang XN, Jazag A, et al. The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. PLoS One. 2012;7(12), e51916.CrossRef
3.
go back to reference Zhu X, Dai Y, Chen Z, Xie J, Zeng W, Lin Y. Knockdown of Pokemon protein expression inhibits hepatocellular carcinoma cell proliferation by suppression of AKT activity. Oncol Res. 2013;20(8):377–81.CrossRef Zhu X, Dai Y, Chen Z, Xie J, Zeng W, Lin Y. Knockdown of Pokemon protein expression inhibits hepatocellular carcinoma cell proliferation by suppression of AKT activity. Oncol Res. 2013;20(8):377–81.CrossRef
4.
go back to reference Liu K, Liu F, Zhang N, Liu S, Jiang Y. Pokemon silencing leads to Bim-mediated anoikis of human hepatoma cell QGY7703. Int J Mol Sci. 2012;13(5):5818–31.CrossRef Liu K, Liu F, Zhang N, Liu S, Jiang Y. Pokemon silencing leads to Bim-mediated anoikis of human hepatoma cell QGY7703. Int J Mol Sci. 2012;13(5):5818–31.CrossRef
5.
go back to reference Zhang YQ, Xiao CX, Lin BY, Shi Y, Liu YP, Liu JJ, et al. Silencing of Pokemon enhances caspase-dependent apoptosis via fas- and mitochondria-mediated pathways in hepatocellular carcinoma cells. PLoS One. 2013;8(7), e68981.CrossRef Zhang YQ, Xiao CX, Lin BY, Shi Y, Liu YP, Liu JJ, et al. Silencing of Pokemon enhances caspase-dependent apoptosis via fas- and mitochondria-mediated pathways in hepatocellular carcinoma cells. PLoS One. 2013;8(7), e68981.CrossRef
6.
go back to reference Jin XL, Sun QS, Liu F, Yang HW, Liu M, Liu HX, et al. MicroRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation. J Cell Biochem. 2013;114(7):1625–33.CrossRef Jin XL, Sun QS, Liu F, Yang HW, Liu M, Liu HX, et al. MicroRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation. J Cell Biochem. 2013;114(7):1625–33.CrossRef
7.
go back to reference Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, et al. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials. 2012;33(34):8893–905.CrossRef Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, et al. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials. 2012;33(34):8893–905.CrossRef
8.
go back to reference Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 1999;81(5):814–21.CrossRef Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 1999;81(5):814–21.CrossRef
9.
go back to reference Yu W, Huang C, Wang Q, Huang T, Ding Y, Ma C, et al. MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-beta1 autoregulation circuitry. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35(11):10943–51.CrossRef Yu W, Huang C, Wang Q, Huang T, Ding Y, Ma C, et al. MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-beta1 autoregulation circuitry. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35(11):10943–51.CrossRef
10.
go back to reference Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer Res. 2014;74(5):1452–62.CrossRef Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer Res. 2014;74(5):1452–62.CrossRef
11.
go back to reference Zhang QL, Tian DA, Xu XJ. Depletion of Pokemon gene inhibits hepatocellular carcinoma cell growth through inhibition of H-ras. Onkologie. 2011;34(10):526–31.CrossRef Zhang QL, Tian DA, Xu XJ. Depletion of Pokemon gene inhibits hepatocellular carcinoma cell growth through inhibition of H-ras. Onkologie. 2011;34(10):526–31.CrossRef
12.
go back to reference Yan Z, Wang J, Wang C, Jiao Y, Qi W, Che S. miR-96/HBP1/Wnt/beta-catenin regulatory circuitry promotes glioma growth. FEBS Lett. 2014;588(17):3038–46.CrossRef Yan Z, Wang J, Wang C, Jiao Y, Qi W, Che S. miR-96/HBP1/Wnt/beta-catenin regulatory circuitry promotes glioma growth. FEBS Lett. 2014;588(17):3038–46.CrossRef
Metadata
Title
RETRACTED ARTICLE: Pokemon and MEF2D co-operationally promote invasion of hepatocellular carcinoma
Authors
Xin Hong
Xing-Yu Hong
Tao Li
Cheng-Yan He
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3744-0

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine